Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 6, 2009, Pages 781-788

  Matzno, Sumio ^a   Nishiguchi, Tomoko ^a   Akiyoshi, Takeshi ^b   Anami, Setsuko ^c   Nakabayashi, Toshikatsu ^a   Matsuyama, Kenji ^b  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAKAI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Apoptosis; N containing bisphosphonates; Protein prenylation; Statins

Indexed keywords

ALENDRONIC ACID; ATORVASTATIN; BISPHOSPHONIC ACID DERIVATIVE; CASPASE 8; DNA; ETIDRONIC ACID; GERANYLGERANIOL; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RISEDRONIC ACID; BONE DENSITY CONSERVATION AGENT; CASPASE; DRUG DERIVATIVE; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL MEMBRANE; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; IMMUNOBLOTTING; MYOBLAST; NONHUMAN; RAT; RAT STRAIN; RAT STRAIN L6; RHABDOMYOLYSIS; SKELETAL MUSCLE; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; ENZYME ACTIVATION; METABOLISM;

ALENDRONATE; ANIMALS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CASPASES; CELL LINE; DIPHOSPHONATES; DNA FRAGMENTATION; DRUG SYNERGISM; ENZYME ACTIVATION; ETIDRONIC ACID; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOBLASTS, SKELETAL; PYRROLES; RATS; RHABDOMYOLYSIS;

EID: 85047684673     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.61.06.0011     Document Type: Article

References (30)

1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
2. Fleisch H. Development of bisphosphonates. Breast Cancer Res 2001; 4: 30-34.
3. Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97-106.
4. Frith JC et al. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12: 1358-1367.
5. Russell RG. Bisphosphonates: mode of action and pharmacology. Pediatrics 2007; 119 (Suppl 2): S150-S162.
6. Luckman SP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-589.
7. van Beek ER et al. Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone 2003; 33: 805-811.
8. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719.
9. Kearney PM, Baigent C. Statins: are any questions unanswered? Curr Opin Lipidol 2006; 17: 418-425.
10. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006; 291: C1208-C1212.
11. Matzno S et al. Statin-induced apoptosis linked with membrane farnesylated Ras smallGprotein depletion, rather than geranylated Rho protein. J Pharm Pharmacol 2005; 57: 1475-1484.
12. Tanriverdi HA et al. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. Eur J Obstet Gynecol Reprod Biol 2005; 120: 63-68.
13. Matzno S et al. Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts. J Lipid Res 1997; 38: 1639-1648.
14. Matzno S et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 2003; 55: 795-802.
15. Sakamoto S et al. Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid. Endocrinology 2004; 145: 2929-2940.
16. 2+-dependentcaspase-12 activation. Life Sci 2006; 78: 1892-1899.
17. van Noorden CJ. The history of Z-VAD-FMK, a tool for understanding the significance of caspase inhibition. Acta Histochem 2001; 103: 241-251.
18. Benford HL et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131-140.
19. Guo RT et al. Bisphosphonates target multiple sites in both cisand trans-prenyltransferases. Proc Natl Acad Sci USA 2007; 104: 10022-10027.
20. Sabbatini M et al. Atorvastatin improves the course of ischemic acute renal failure in aging rats. J Am Soc Nephrol 2004; 15: 901-909.
21. Guijarro C et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83: 490-500.
22. Fisher JE et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96: 133-138.
23. Reszka AA et al. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999; 274: 34967-34973.
24. van Beek ER et al. Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structureactivity relationships. Bone 1998; 23: 437-442.
25. Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord 2002; 2: 20-33.
26. Cummings SR et al. Alendronate and atrial fibrillation. N Engl J Med 2007; 356: 1895-1896.
27. Black DM et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
28. Heckbert SR et al. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008; 168: 826-831.
29. Pavlakis N et al. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3: CD003474.
30. Yuen KK et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; 4: CD006250.